Mathematical Models in Decision Analysis

Infection Control and Hospital Epidemiology

Volumn 18, Issue 1, 1997, Pages 65-73

  Tom, Eric ^a   Schulman, Kevin A ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECISION SUPPORT SYSTEM; DECISION TREE; EPIDEMIOLOGY; FUZZY LOGIC; HUMAN; MONTE CARLO METHOD; OUTCOME ASSESSMENT; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; SURVIVAL;

DECISION SUPPORT TECHNIQUES; DECISION TREES; EPIDEMIOLOGIC METHODS; FUZZY LOGIC; HUMANS; MARKOV CHAINS; MODELS, STATISTICAL; MONTE CARLO METHOD; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

EID: 0030641417     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.2307/30141966     Document Type: Article

References (28)

1. Sox HC, Blatt MA, Higgins MC, Marton KI. Medical Decision Making. Stoneham, MA: Butterworth-Heinemann; 1988.
2. DeGroot MH. Probability and Statistics. 2nd ed. Reading, MA: Addison Wesley; 1986.
3. Lieu TA, Fleisher GR, Schwartz JS. Clinical performance and effect on treatment rates of latex agglutination testing for streptococcal pharyngitis in an emergency department. Pediatr Infect Dis 1986;91:713-718.
4. Ferguson BM, Keown PA. An introduction to utility measurement in health care. Infect Control Hosp Epidemiol 1995;16: 240-247.
5. Schulman KA, Glick HA, Rubin H, Eisenberg JM. Cost-effectiveness of HA-1A monoclonal antibody for gram-negative sepsis: economic assessment of a new therapeutic agent. JAMA 1991;266:3466-3471.
6. Bailey NTJ. The Elements of Stochastic Processes With Application to the Natural Sciences. New York, NY: John Wiley & Sons, Inc; 1964.
7. Feller W. An Introduction to Probability Theory and Its Application. VoI I. New York, NY: John Wiley & Sons, Inc; 1957.
8. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983;3:419-458.
9. Sonnenberg FA, Pauker SG. Decision Maker: An Advanced Personal Computer Tool for Clinical Decision Analysis. Proceedings of the 11th annual symposium on Computer Applications in Medical Care; 1987. Washington, DC: IEEE Computer Society.
10. Glick H, Heyse JF, Thompson D, Epstein RS, Smith ME, Oster G. A model for evaluating the cost-effectiveness of cholesterol-lowering treatment. Int J Technol Assess Health Care 1992;8: 719-734.
11. Sarasin FP, Bounameaux H. Duration of oral anticoagulant therapy after proximal deep vein thrombosis: a decision analysis. Thromb Haemost 1994;71:286-291.
12. Thompson EA. Monte-Carlo likelihood in genetic mapping. Statistical Science 1994:355-366.
13. Schulman KA, McDonald RC, Lynn LA, Frank I, Christakis NA, Schwartz S. Screening surgeons for HIV infection: assessment of a potential public health program. Infect Control Hosp Epidemiol 1994;15:147-155.
14. Elandt-Johnson RC, Johnson NL. Survival Models and Data Analysis. New York, NY: John Wiley & Sons, Inc; 1980.
15. Stenzel JP, Green TP, Bradley PF, et al. Percutaneous central venous catheterization in a pediatric intensive care unit: a survival analysis of complications. Crit Care Med 1989;17:984-988.
16. Maki DG, Ringer M. Evaluations of dressing regiments for prevention of infection with peripheral intravenous catheters. JAMA 1987;258:2396-2403.
17. Raad I, Unphrey J, Kan A, et al. The duration of placement as a predictor of peripheral and pulmonary arterial catheter infections. J Hosp Infect 1993;23:17-26.
18. Madge P, Paton JY, McColl JH, et al. Prospective controlled study of four infection control procedures to prevent nosocomial infection with respiratory syncytial virus. Lancet 1992;340:1079-1083.
19. Schulman KA, Lynn LA, Glick HA, Eisenberg JM. Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Ann Intern Med 1991;114:798-802.
20. Cole BF, Gelber RD, Anderson KM. Parametric approaches to quality-adjusted survival analysis. Biometrics 1994;50:621-631.
21. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 1993;11:1866-1872.
22. Kuntz KM, Weinstein MC. Life expectancy biases in clinical decision modeling. Med Decis Making 1995;15:158-169.
23. Yager RR, Ovchinnikov S, Tong RM, Nguyen HT. Fuzzy Sets and Applications: Selected Papers by LA Zadeh. New York, NY: John Wiley & Sons, Inc; 1987.
24. Suryanarayanan S, Reddy NP, Canilang EP. A fuzzy logic diagnosis system for classification of pharyngeal dysphagia. Int J Biomed Comput 1995;38:207-215.
25. Shiomi S, Kuroki T, Jomura H, et al. Diagnosis of chronic liver disease from live scintiscans by fuzzy reasoning. J Nucl Med 1995;36:593-598.
26. Steimann F, Hayde M, Panzenböck B, Adlassnig KP, Pollak A. Fuzzy logic support for seriodiagnosis: the onset program. IEEE Engineering in Medicine and Biology 1994;13:705-709.
27. Briggs A, Sculpher M. Sensitivity analysis in economic evaluation: a review of published studies. Health Econ 1995;4:355-371.
28. Glick H, Kington R. Pharmacoeconomics: principles and basic techniques of economic analysis. Drug Epidemiology and Post-Marketing Surveillance 1992:115-124.